GEN News Highlights

Exquiron Gets New Diverse Screening Compound Library from Enamine

(Page
1
of
1)

Enamine, a Ukraine-based provider of screening compounds, chemical building blocks, and discovery services, will be bestowing Exquiron Biotech with a novel diverse screening compound library, which will be made available by Exquiron to screening clients for hit discovery projects.

The library provided by Enamine reportedly includes a high number of diverse drug-like compounds. Exquiron and its clients will also have access to Enamine’s full range of chemistry expertise for post-screening follow-up.

“Offering high-quality chemistry to our clients is crucial,” Serge Parel, Ph.D., vp of chemistry and research informatics at Exquiron, commented. “We are impressed by the quality and novelty of Enamine’s compounds, coupled with their logistics and support services. Together we can offer clients excellent value.”

Exquiron describes itself as a newly formed Swiss company with service offerings in early stage drug discovery. Its services span from development of hit identification and profiling assays to compound selection, high-throughput screening, hit profiling and characterization, and SAR expansion.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.